Carbubarb

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 10:38, 11 November 2014 (Updating {{drugbox}} (changes to verified and watched fields - updated 'ChEMBL_Ref', 'Verifiedfields', 'Watchedfields') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Carbubarb
Clinical data
Trade namesNogexan
Other namesCarbubarbital
ATC code
  • none
Identifiers
  • 2-(5-butyl-2,4,6-trioxo-1,3-diazinan-5-yl)ethyl carbamate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H17N3O5
Molar mass271.270 g/mol g·mol−1
3D model (JSmol)
  • CCCCC1(C(=O)NC(=O)NC1=O)CCOC(=O)N
  • InChI=1S/C11H17N3O5/c1-2-3-4-11(5-6-19-9(12)17)7(15)13-10(18)14-8(11)16/h2-6H2,1H3,(H2,12,17)(H2,13,14,15,16,18) checkY
  • Key:ZWGPHQZXAPWKOV-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Carbubarb (Carbubarbital, trade name Nogexan) is a carbamate-substituted barbiturate derivative, which has sedative effects.[1]

References

  1. ^ US patent 4428887, Tou, J. S. & Schleppnik, A. A., "Method of producing mono-substituted terminal diesters", issued 1984-01-31, assigned to Monsanto